Companies
Defined Bioscience
the HiDef media line, including S8 stem-cell suspension medium and a DMEM/F12 basal medium tested across more than 100 hiPSC and hESC lines, is specifically formulated for stem-cell and iPSC applications rather than general biopharma manufacturing.
- Country
- United States
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| cleanroom-facilities | ✓ | ✓ | ✓ |
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemamoa-chinanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $1.5M SBIR grant from the NIH (2022), plus additional seed and grant funding rounds confirmed through April 2025 | definedbioscience.com · caplight.com |
| Headcount | Between 6 and 18 employees medium confidence | caplight.com · inknowvation.com |
| Revenue | $0.5M-$1M range medium confidence | inknowvation.com |
| Headquarters | San Diego, California | definedbioscience.com · caplight.com |
| Founded | 2020 (some sources cite 2019) | definedbioscience.com · caplight.com |
Independent sources: caplight.com · inknowvation.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Cell culture media (B2B consumable) | cleanroom-facilities | Low | → |
| Induced pluripotent stem cells (iPSC) | regenerative-personalized | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.